March 2023

The first clinical results of a Phase 3 trial with mannan-conjugated polymerized allergens have been presented at the AAAAI meeting held last February 24-27 in San Antonio, Texas. These preparations represent a new generation of dendritic cell-targeted allergen-specific immunotherapy vaccines developed by INMUNOTEK.
More info

February 2023

Pathogens publishes a comprehensive literature review on MV140, a sublingual mucosal bacterial vaccine produced by INMUNOTEK. MV140 is indicated for immunoprophylaxis of recurrent uncomplicated urinary tract infections.
More info

February 2023

New concepts in allergen-specific immunotherapy arising from discoveries related to the memory of innate immunity are reviewed in Clinical & Experimental Allergy. An analogy is drawn between trained immunity-based vaccines (TIbV) and trained immunity-based allergen vaccines (TIbAV) when the latter have, in addition to allergens, components that induce the training of innate immunity cells.
More info

December 2022

The journal Current Opinion in Allergy and Clinical Immunology publishes a review on recent advances in the prevention of viral respiratory infections in young children by bacterial immunotherapy based on the induction of trained immunity. These infections are a frequent cause of bronchiolitis and wheezing in young children.
More info

November 2022

The result of the combination of Candida albicans (V132) with the polybacterial vaccine MV140 against recurrent urinary tract infections has been published in Frontiers in Immunology. This research is a continuation of a previous study and aims to deepen the immunological mechanisms of V132+MV140, a vaccine oriented to the treatment of recurrent infections of the genito-urinary tract.
More info

October 2022

An interesting epidemiological study has been published in the Journal of Asthma and Allergy on pollen sensitisation profiles in a population with identical exposure but different origins in order to assess the influence of environmental and ancestral factors. The study was carried out in a town in Murcia (Spain) on the resident population of Spanish and Moroccan origin.
More info

September 2022

A study conducted in Colombia to evaluate immunotherapy to house dust mites, including Blomia tropicalis, has been published in WAOJ (World Allergy Organization Journal). The study has assessed the efficacy and safety of ALXOID of three mites in a prospective trial with 250 patients led by Dr. Cardona (University of Antioquia) with the collaboration of INMUNOTEK.
More info

May 2022

Allergy publishes the results of the first-in-human clinical trial (Phase 2) aimed at addressing the safety and optimal dose of the new mannan-house dust mite allergoid vaccines for subcutaneous and sublingual immunotherapy. The study, conducted in the Mediterranean coast of Spain and coordinated by Dr. Antonio Nieto as principal investigator, involved 13 allergy centers and 196 patients.
More info

March 2022

NEJM Evidence highlights in an Editorial the results of the clinical trial with MV140 recently published in that journal. MV140 showed its safety and efficacy in a randomized, double-blind, placebo-controlled, Phase 3 trial conducted in Spain and the United Kingdom.
More info

February 2022

The reduction of recurrent urinary tract infections after treatment with MV140 (UROMUNE) represents a significant health saving according to a study published in Urologia Internationalis. The savings have been calculated taking into account the healthcare costs and medication associated with this type of infection in Spain. This study was carried out at the Urology Department of the Albacete University Hospital Complex.
More info